One of the main reasons for the development of many diabetes complications is chronic hyperglycemia, which results in a number of mechanisms generating excessive production of reactive oxygen (ROS) and cause of avalanche growth of free radicals. Excessive production of ROS in the body or insufficient antioxidative barrier of the body can lead to intracellular damage. Intense physical exertion, may also violate the dynamic balance of prooxidants and antioxidants. The aim of the study was to verify the level of prooxidative-antioxidative balance in men with type 1 diabetes versus control group after maximum intensity exercise. The study included 30 men with type 1 diabetes treated with a personal insulin pumps aged 23.4 ± 5.1 with 11.4 ± 6.0 years of diabetes duration and mean HbA1c 7.2 ± 0.9%. 23 healthy men aged 24.7 ± 2.9 years were included in the control group. The march-running test on the treadmill to determine the maximal oxygen consumption (VO2max) was performed. Before and 60 minutes after the test total antioxidant status TAS (Immundiagnostik AG ImAnOx test, KC5200) and total prooxidative status TOS (test by Immundiagnostik AG PerOx, KC5100) in plasma were measured. The average level of VO2max (44.7 ± 5.7 vs. 56.0 ± 7.3) in the group of people with diabetes was significantly lower (p = 0.000) compared to the control group. Both before and after maximum exercise higher values of TOS levels (p = 0.000) was observed in patients with T1DM. The level of TAS before exercise was comparable in both groups, whereas after exercise it was significantly higher in the control group (p = 0.0000). In the diabetic group after maximum effort a decrease while in the control group a slight increase in TAS level was observed (p = 0.0174). The TOS/TAS [%] ratio was significantly higher both before and after the maximum effort in the T1DM group. Results of our study underline importance of increase oxidative stress in T1DM patients accompanying intense exercise.


B. Matejko: Other Relationship; Self; Dexcom, Inc., Roche Diabetes Care. &. Tota: None. M. Morawska: None. S. Mrozinska: Other Relationship; Self; Roche Diabetes Care. W. Pilch: None. T. Palka: None. B. Kiec-Wilk: None. M. Malecki: None. T. Klupa: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Roche Diabetes Care, Sanofi. Employee; Spouse/Partner; Ascensia Diabetes Care.


Polish Diabetes Association (2017); University of Physical Education (185/BS/INB/2018)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at